NCT07590986 Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
| NCT ID | NCT07590986 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université Catholique de Louvain |
| Condition | Myeloproliferative Neoplasm (MPN) |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-05 |
| Primary Completion | 2036-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2026-05 with a primary completion date of 2036-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN. The main questions it aims to answer are: * Are there T cells in the bone marrow that can recognize MPN cells? * Which targets (antigens) on MPN cells are recognized by these immune cells? * Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies? Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison. By providing blood and bone marrow samples, participants will: * Allow researchers to study immune cells and genetic material from these samples * Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN. Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.
Eligibility Criteria
Inclusion Criteria: * Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN. * Patients not previously diagnosed with a haematological disease as controls Exclusion Criteria: * Patients with any other hematological malignancy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07590986 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloproliferative Neoplasm (MPN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07590986 currently recruiting?
Yes, NCT07590986 is actively recruiting participants. Contact the research team at sophie.lucas@uclouvain.be for enrollment information.
Where is the NCT07590986 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT07590986 clinical trial?
NCT07590986 is sponsored by Université Catholique de Louvain. The trial plans to enroll 150 participants.